Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AE-M

Drug Profile

AE-M

Alternative Names: AE-08; AE-08 vaccine; AE-M vaccine; Ii-key/gp100

Latest Information Update: 16 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antigen Express
  • Developer NuGenerex Immuno-Oncology
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jan 2020 Generex Biotechnology Corporation plans a phase II trial for Malignant-melanoma (Combination therapy) in 2020
  • 15 Oct 2019 Generex Biotechnology announces intention to reactivate the melanoma programme by November 2019
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top